May 2, 2019
Gilead net income $2B
@GileadSciences said Thursday its total revenues were $5.3 billion in 2019 compared to $5.1 billion in 2018, with net income of $2.0 billion compared to $1.5 billion in 2018.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
May 2, 2019
Sanofi’s dengue vaccine approved in USA
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
May 2, 2019
Lilly presents new Emgality data
Eli Lilly will present 19 scientific abstracts for headache preventive drug Emgality (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019.
April 25, 2019
Moleculin recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First
Patient Showing Positive Initial Treatment
April 23, 2019
Trovagene’s combo of onvansertib, venetoclax shows synergy in cell model of Venetoclax-Resistant AML
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
April 22, 2019
Lilly’s drug Taltz for nr-axSpA meets endpoints in Phase 3 testing, approval application expected this year
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.
April 15, 2019
BiondVax universal flu vaccine patent application accepted in Australia
BiondVax Pharmaceuticals got its patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate accepted in Australia.
April 8, 2019
The FDA granted approval of Dovato to ViiV Healthcare
The U.S. Food and Drug Administration Monday approved Dovato, two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
April 8, 2019
Brief: Unither Therapeutics drops esuberaprost tablets development for pulmonary arterial hypertension
United Therapeutics Corporation Monday said that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.
April 5, 2019
Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients
Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid…